Tango Therapeutics, Inc.

NASDAQ:TNGX

Biotechnology

Healthcare
$21.89 -10.03%

-$3.24 today

Market cap
$3.71B
Beta
1.19
P/E (TTM)
-38.9
EPS (TTM)
-$0.75
52W Low $4.60High $34.39

Volume 2.75M

Average 3.67M

TNGX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Tango Therapeutics, Inc.NASDAQ: TNGX

Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026

Financing cash flow dips below year-ago levels

Q3 FY2026 financing cash flow of $2.4M fell 5.5% year over year, behind the +23701.4% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.6% from the prior quarter. Over 3 fiscal years it compounded at +416.5% a year.

Context

  • Financing cash flow amounted to 356.7% of revenue in FY2025, up 243.4 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of +23701.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.4M-99.6% QoQ
Last fiscal yearDec 2025
$222.5M+366.8% YoY
LTMSep 2026
$974.19M+23701.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.5%——
1 year+366.8%——
3-year CAGR+416.5%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
222.5M USD
Year-over-year change
+366.8%
4-year CAGR
-11.2%

Financing Cash Flow vs competitors

How TNGX compares with its peers on the latest reported figures

  • TNGX's LTM Sep 2026 financing cash flow of $974.19M is the 2nd largest of the 11 companies compared; the peer median is $153.02M.
  • Its year-over-year change of +23701.4% is the 2nd highest of 11, against a peer median of +69.5%.
  • Over three fiscal years its annual growth of +416.5% compares with a peer median of +26.8%.
TNGX Competitors Peer median
Financing Cash Flow for TNGX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$3.02B +150.2%+27.3%—
TNGXTango Therapeutics, Inc.LTM Sep 2026$974.19M +23701.4%+416.5%—
ERASErasca, Inc.LTM Sep 2026$845.81M +63879.3%-77.6%—
RLAYRelay Therapeutics, Inc.LTM Jun 2026$463.47M +110.3%-82.3%4478.0%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$261.21M +28.6%+26.8%37.2%
NUVBNuvation Bio Inc.LTM Jun 2026$179.14M -6.5%+434.4%105.4%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.91M +1085.3%+379.4%364.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.66M -51.5%-16.6%179.5%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$24.66M +9371.4%+212.3%147.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$4.82M -98.6%-32.6%2.1%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$439K -100.4%——
Peer median (excluding TNGX) $153.02M+69.5%+26.8%147.5%

Competitors are the stored peer set for TNGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(58.24M)(108.18M)(101.74M)(130.3M)(101.59M)
Depreciation & Amortization897K1.61M2.42M2.5M2.28M
Deferred Income Tax00000
Stock-Based Compensation7.83M14.23M19.08M28.9M26.43M
Change in Working Capital(11.35M)(18.49M)(37.97M)(31.75M)(67.2M)
Accounts Receivables002M00
Inventory00000
Accounts Payables1.23M1.1M(1.71M)(1.18M)(825K)
Other Working Capital(12.58M)(19.59M)(38.26M)(30.56M)(66.37M)
Other Non-Cash Items1.32M1.75M234K(849K)1.2M
Operating Cash Flow(59.53M)(109.08M)(117.98M)(131.5M)(138.89M)
Capital Expenditures(1.84M)(7.69M)(1.53M)(754K)(1.05M)
Acquisitions (Net)00000
Purchases of Investments(372.36M)(208.5M)(310.57M)(240.89M)(264.46M)
Sales of Investments190.76M242.6M353.53M327.77M224.64M
Other Investing Activities00000
Investing Cash Flow(183.43M)26.4M41.43M86.13M(40.87M)
Debt Repayment342.11M0000
Common Stock Issued0080.02M41.72M222.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(14.78M)1.62M2.39M5.94M(36K)
Financing Cash Flow357.33M1.62M82.41M47.66M222.5M
Effect of Forex Changes00000
Net Change in Cash114.36M(81.07M)5.85M2.29M42.75M
Free Cash Flow(61.36M)(116.77M)(119.51M)(132.26M)(139.93M)

Tango Therapeutics, Inc.

NASDAQ:TNGX

Intrinsic Alpha fair value

Locked

Current Price

$21.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.